A phase 1b study of SL-172154 in combination with liposomal doxorubicin to evaluate safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamics of the combination
Latest Information Update: 19 Aug 2022
At a glance
- Drugs Doxorubicin liposomal (Primary) ; SL 172154 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Shattuck Labs
- 11 Aug 2022 According to a Shattuck Labs media release, starting dose of SL-172154 in this trial is 3.0 mg/kg.
- 11 Aug 2022 According to a Shattuck Labs media release, enrollment in the trial is expected to begin in Q3 2022 with initial combination data expected in 1H 2023.
- 11 Aug 2022 According to a Shattuck Labs media release, the trial is expected to begin in the third quarter of 2022.